KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
| Name |
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| |
|---|---|---|---|---|---|---|
| 579 USD | +0.93% | +5.60% | +9.10% | 11.69% | ||
| 22.16 USD | +6.72% | +1.15% | -27.58% | 11.15% | ||
| 55.32 USD | +2.62% | -0.90% | -11.88% | 8.55% | ||
| 22.38 USD | +4.65% | -7.47% | -18.07% | 8.03% | ||
| 3.745 USD | +0.94% | -6.02% | -34.55% | 6.97% | ||
| 2.255 USD | +5.87% | +3.25% | -33.78% | 4.87% | ||
| 5.475 USD | +2.91% | -2.14% | -45.90% | 4.83% | ||
| 160.6 USD | +0.59% | -4.78% | +3.16% | 4.81% | ||
| 4.89 USD | +10.51% | +2.09% | -44.92% | 4.71% | ||
| 6.365 USD | +3.33% | -8.10% | -54.45% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Jurisdiction | |
| Replication Method | |
| Replication Model | |
| Date of creation |
2022-01-11
|
| Dividend Policy | |
| Geographical Focus |
AuM evolution ( 2023-10-30 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF
